

AFO efficacy in Cerebral Palsy.

Gepubliceerd: 03-05-2012 Laatste bijgewerkt: 19-03-2025

An Ankle-foot orthosis (AFO) is a commonly prescribed rehabilitation intervention in children with Cerebral Palsy (CP). AFOs have the purpose to reduce gait deviations in order to enable or improve standing and walking. Although AFOs in children...

| | |
|-----------------------------|-----------------------|
| Ethische beoordeling | Positief advies |
| Status | Werving gestart |
| Type aandoening | - |
| Onderzoekstype | Interventie onderzoek |

Samenvatting

ID

NL-OMON27398

Bron

Nationaal Trial Register

Verkorte titel

EVO-CP

Aandoening

Cerebral Palsy, Cerebrale Parese; children, kinderen; orthotic devices, orthesen; treatment outcome, behandeluitkomsten; mobility, mobiliteit

Ondersteuning

Primaire sponsor: VU University Medical Center

Overige ondersteuning: Johanna Kinderfonds
Phelps Stichting voor spastici

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

1. Energy cost of walking (assessed with the Energy Cost of Walking Test (ECWT));

2. The subject's daily activity (assessed with the StepWatch Activity Monitor).

Toelichting onderzoek

Achtergrond van het onderzoek

BACKGROUND:

An ankle-foot orthosis (AFO) is a commonly prescribed rehabilitation intervention in Children with Cerebral Palsy (CP). AFOs have the purpose to reduce gait deviations in order to enable or improve standing and walking, thereby enhancing the child's mobility and participation. Although AFOs in children with CP are commonly prescribed, insight in underlying working mechanisms and a clear concept of AFO design in relation to prescription goals is largely lacking. At present, the decision-making process of AFO prescription seems to rely primarily on current best available evidence and expert's experience and opinion, resulting in differences in AFO design. Literature shows that AFO use is not always effective in children with CP and can even have detrimental effects on the child's functioning, e.g. by increasing energy cost of walking or reducing walking speed. This suggests that AFO prescription is inadequate in some patients, and underlines the importance and urgency of acquiring more knowledge about the working mechanisms of AFOs. This requires a extensive evaluation of AFO efficacy on a broad range of outcome measures, i.e. using outcome measures that are related to both components of the International Classification of Functioning, Disability and Health (ICF); 'body functions and structures' and 'activities and participation'.

OBJECTIVE:

The primary objective of this study is to evaluate AFO efficacy in children with spastic CP using outcome measures related to ICF the components of 'body functions and structures' and 'activities and participation'. The secondary aim is to identify prognostic factors for success of AFO treatment on outcome measures related to the ICF component 'activities and participation' in children with spastic CP.

PARTICIPANTS:

Children with spastic CP will be recruited from Department of Rehabilitation of the VU University Medical Center, Amsterdam, the Netherlands. Subjects will be aged between 6 and 14 years old, walking with flexed knee pattern, and classified as I or II according to the Gross Motor Function Classification System (GMFCS).

DESIGN:

This is a pre-post experimental study. Baseline measurements (T0) will be done while subjects wear their current (old) AFO. Then, the intervention AFO will be prescribed, of which stiffness (K) will be varied (n=3, rigid, stiff and flexible). Sequence of AFO stiffness will be blockrandomized (3x2x1=6 blocks). Subjects will accommodate to each AFO stiffness for 4-8 weeks, after which AFO efficacy will be tested (T1K1, T1K2 and T1K3). Then, the subject's optimal AFO will be selected and subjects will wear this optimal AFO for 12-20 weeks. After this period, follow-up measurements (T2) will be done.

INTERVENTION:

Subjects will get an Floor Reaction Orthosis (FRO), composed out of pre-preg material (e.g. impregnated carbon fibres), which will be fabricated with integrated Neuro Swing® system ankle joint. This system has an adjustable spring force, alignment, and range of motion of the ankle joint. This study will investigate the effects of varying stiffness (spring force) of the AFO on gait to select the subject's optimal AFO.

OUTCOME MEASUREMENTS:

Primary study parameters of this study are:

1. Energy cost of walking (J/kg/m);
2. The child's daily activity (steps/day).

Doel van het onderzoek

An Ankle-foot orthosis (AFO) is a commonly prescribed rehabilitation intervention in children with Cerebral Palsy (CP). AFOs have the purpose to reduce gait deviations in order to enable or improve standing and walking. Although AFOs in children with CP are commonly prescribed, insight in underlying working mechanisms and a clear concept of AFO design in relation to prescription goals is largely lacking. It is hypothesized that acquiring more knowledge about underlying working mechanisms by doing an extensive evaluation of AFO efficacy could improve orthotic management in children with CP.

Onderzoeksopzet

1. Baseline (T0): Consists of three measurement moments with two weeks in between (respectively the moments of casting of the leg, fitting the new AFO and delivery of the new AFO;

2. T1K1, T1K2, T1K3: Evaluation measurements of each stiffness (K1,K2,K3) stiffness is worn for 4 weeks. At T1K3, the third stiffness will be evaluated and most optimal stiffness will be selected;

3. T2Kopt; follow-up measurements three months after selecting the optimal AFO.

Onderzoeksproduct en/of interventie

Children will be prescribed a Floor Reaction Orthosis (FRO) that is made out of pre-preg materials. This FRO will be fabricated with an integrated Neuro Swing system ankle joint. Thus to the system's adjustable spring force, alignment and range of motion of the ankle joint, AFO properties can be varied within the same orthosis. This study will investigate the effects of varying stiffness of an AFO in order to select the optimal AFO stiffness for each subject.

Contactpersonen

Publiek

Postbus 1057
Yvette Kerkum
Amsterdam 1007 MB
The Netherlands
+31 (0)20 4443062

Wetenschappelijk

Postbus 1057
Yvette Kerkum
Amsterdam 1007 MB
The Netherlands
+31 (0)20 4443062

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

Inclusion criteria for enrolling the study are:

1. Diagnosis of spastic CP;
2. A gait pattern that is characterized by excessive knee flexion;
3. Age range: 6-14 years;
4. Current AFO use > 1 year;
5. Gross motor function classification of I or II according to the Gross Motor Function Classification System (GMFCS);
6. Ability to walk independently for at least 5 minutes at a comfortable walking speed.

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

1. Any orthopedic surgery or other surgical interventions that might influence mobility in the past six months;
2. Botulinum Toxin A injections in the past three months;
3. Intrathecal Baclofen therapy in the last six months or selective dorsal rhizotomy in the past year;
4. Impairments that could contra indicate fitness testing;
5. Plantarflexion contractures;
6. A knee flexion contracture >10 deg;
7. Hip endorotation <20 deg in midstance;
8. Other medical conditions influencing mobility;
9. Severe behavioural problems.

Onderzoeksopzet

Opzet

Type: Interventie onderzoek

| | |
|------------------|-------------------------|
| Onderzoeksmodel: | Parallel |
| Toewijzing: | N.v.t. / één studie arm |
| Blinding: | Open / niet geblindeerd |
| Controle: | N.v.t. / onbekend |

Deelname

| | |
|-------------------------|----------------------|
| Nederland | |
| Status: | Werving gestart |
| (Verwachte) startdatum: | 01-04-2012 |
| Aantal proefpersonen: | 32 |
| Type: | Verwachte startdatum |

Ethische beoordeling

| | |
|-----------------|------------------|
| Positief advies | |
| Datum: | 03-05-2012 |
| Soort: | Eerste indiening |

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 37433
Bron: ToetsingOnline
Titel:

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

| Register | ID |
|----------|--|
| NTR-new | NL3265 |
| NTR-old | NTR3418 |
| CCMO | NL37940.029.11 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |
| | 6 - AFO efficacy in Cerebral Palsy. 30-05-2025 |

Register

OMON

ID

NL-OMON37433

Resultaten

Samenvatting resultaten

N/A